vs
博士伦（BLCO）与Innovative Eyewear Inc（LUCY）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Innovative Eyewear Inc的1463.8倍（$1.4B vs $959.8K）。博士伦净利率更高（-4.1% vs -194.8%，领先190.7%）。Innovative Eyewear Inc同比增速更快（39.0% vs 9.8%）。博士伦自由现金流更多（$60.0M vs $-1.4M）。过去两年Innovative Eyewear Inc的营收复合增速更高（58.2% vs 13.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
General Eyewear是一家总部位于伦敦的眼镜企业与品牌，由弗雷泽·莱恩于1990年代末创立。品牌最初名为Arckiv，主打原创眼镜设计，尤其在复古眼镜品类拥有深厚的专业积淀，是眼镜行业颇具特色的专业品牌。
BLCO vs LUCY — 直观对比
营收规模更大
BLCO
是对方的1463.8倍
$959.8K
营收增速更快
LUCY
高出29.2%
9.8%
净利率更高
BLCO
高出190.7%
-194.8%
自由现金流更多
BLCO
多$61.4M
$-1.4M
两年增速更快
LUCY
近两年复合增速
13.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $959.8K |
| 净利润 | $-58.0M | $-1.9M |
| 毛利率 | — | 12.0% |
| 营业利润率 | 8.0% | — |
| 净利率 | -4.1% | -194.8% |
| 营收同比 | 9.8% | 39.0% |
| 净利润同比 | -1833.3% | 12.0% |
| 每股收益（稀释后） | $-0.16 | $-0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOLUCY
| Q4 25 | $1.4B | $959.8K | ||
| Q3 25 | $1.3B | $668.1K | ||
| Q2 25 | $1.3B | $579.2K | ||
| Q1 25 | $1.1B | $454.5K | ||
| Q4 24 | $1.3B | $690.7K | ||
| Q3 24 | $1.2B | $253.6K | ||
| Q2 24 | $1.2B | $308.7K | ||
| Q1 24 | $1.1B | $383.5K |
净利润BLCOLUCY
| Q4 25 | $-58.0M | $-1.9M | ||
| Q3 25 | $-28.0M | $-1.8M | ||
| Q2 25 | $-62.0M | $-2.1M | ||
| Q1 25 | $-212.0M | $-1.8M | ||
| Q4 24 | $-3.0M | $-2.1M | ||
| Q3 24 | $4.0M | $-1.7M | ||
| Q2 24 | $-151.0M | $-1.9M | ||
| Q1 24 | $-167.0M | $-2.0M |
毛利率BLCOLUCY
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | -2.2% | ||
| Q1 25 | — | 48.5% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 23.4% | ||
| Q2 24 | — | 17.9% | ||
| Q1 24 | — | 1.8% |
营业利润率BLCOLUCY
| Q4 25 | 8.0% | — | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | -0.9% | — | ||
| Q1 25 | -7.3% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 0.5% | — |
净利率BLCOLUCY
| Q4 25 | -4.1% | -194.8% | ||
| Q3 25 | -2.2% | -274.8% | ||
| Q2 25 | -4.9% | -363.6% | ||
| Q1 25 | -18.6% | -391.4% | ||
| Q4 24 | -0.2% | -307.8% | ||
| Q3 24 | 0.3% | -678.5% | ||
| Q2 24 | -12.4% | -631.2% | ||
| Q1 24 | -15.2% | -514.1% |
每股收益（稀释后）BLCOLUCY
| Q4 25 | $-0.16 | $-0.14 | ||
| Q3 25 | $-0.08 | $-0.38 | ||
| Q2 25 | $-0.18 | $-0.66 | ||
| Q1 25 | $-0.60 | $-0.72 | ||
| Q4 24 | $-0.00 | $0.26 | ||
| Q3 24 | $0.01 | $-0.99 | ||
| Q2 24 | $-0.43 | $-1.87 | ||
| Q1 24 | $-0.48 | $-2.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $6.5M |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $9.1M |
| 总资产 | $14.0B | $10.1M |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCOLUCY
| Q4 25 | $383.0M | $6.5M | ||
| Q3 25 | $310.0M | $6.7M | ||
| Q2 25 | $266.0M | $7.6M | ||
| Q1 25 | $202.0M | $5.3M | ||
| Q4 24 | $305.0M | $2.6M | ||
| Q3 24 | $329.0M | $4.5M | ||
| Q2 24 | $285.0M | $5.9M | ||
| Q1 24 | $315.0M | $2.6M |
总债务BLCOLUCY
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益BLCOLUCY
| Q4 25 | $6.4B | $9.1M | ||
| Q3 25 | $6.4B | $10.3M | ||
| Q2 25 | $6.4B | $11.3M | ||
| Q1 25 | $6.4B | $7.5M | ||
| Q4 24 | $6.5B | $9.1M | ||
| Q3 24 | $6.6B | $10.9M | ||
| Q2 24 | $6.5B | $7.3M | ||
| Q1 24 | $6.7B | $3.9M |
总资产BLCOLUCY
| Q4 25 | $14.0B | $10.1M | ||
| Q3 25 | $13.8B | $11.2M | ||
| Q2 25 | $13.8B | $11.9M | ||
| Q1 25 | $13.4B | $7.9M | ||
| Q4 24 | $13.5B | $9.8M | ||
| Q3 24 | $13.5B | $11.6M | ||
| Q2 24 | $13.3B | $7.9M | ||
| Q1 24 | $13.3B | $4.8M |
负债/权益比BLCOLUCY
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $-1.4M |
| 自由现金流率自由现金流/营收 | 4.3% | -142.5% |
| 资本支出强度资本支出/营收 | 5.4% | 1.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | — |
8季度趋势，按日历期对齐
经营现金流BLCOLUCY
| Q4 25 | $136.0M | $-1.4M | ||
| Q3 25 | $137.0M | $-1.5M | ||
| Q2 25 | $35.0M | $-2.1M | ||
| Q1 25 | $-25.0M | $-2.3M | ||
| Q4 24 | $22.0M | $-1.9M | ||
| Q3 24 | $154.0M | $-1.4M | ||
| Q2 24 | $15.0M | $-1.9M | ||
| Q1 24 | $41.0M | $-1.5M |
自由现金流BLCOLUCY
| Q4 25 | $60.0M | $-1.4M | ||
| Q3 25 | $63.0M | $-1.5M | ||
| Q2 25 | $-54.0M | — | ||
| Q1 25 | $-135.0M | $-2.4M | ||
| Q4 24 | $-70.0M | $-2.0M | ||
| Q3 24 | $94.0M | — | ||
| Q2 24 | $-57.0M | $-1.9M | ||
| Q1 24 | $-26.0M | $-1.5M |
自由现金流率BLCOLUCY
| Q4 25 | 4.3% | -142.5% | ||
| Q3 25 | 4.9% | -226.3% | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -11.9% | -517.4% | ||
| Q4 24 | -5.5% | -285.2% | ||
| Q3 24 | 7.9% | — | ||
| Q2 24 | -4.7% | -626.1% | ||
| Q1 24 | -2.4% | -391.1% |
资本支出强度BLCOLUCY
| Q4 25 | 5.4% | 1.8% | ||
| Q3 25 | 5.8% | 2.2% | ||
| Q2 25 | 7.0% | 0.0% | ||
| Q1 25 | 9.7% | 8.9% | ||
| Q4 24 | 7.2% | 3.8% | ||
| Q3 24 | 5.0% | 0.0% | ||
| Q2 24 | 5.9% | 1.1% | ||
| Q1 24 | 6.1% | 8.4% |
现金转化率BLCOLUCY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
LUCY
暂无分部数据
